Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | DRD2 | P14416 | 2/20 | 0.48 |
| ▸ | DRD3 | P35462 | 2/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | SORD | Q00796 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19012643 | 0.85 | KDM4E (0.58) | KDM4EMAPTDRD2DRD3HTR1A | |
| SCHEMBL11637734 | 0.84 | KDM4E (0.65) | KDM4EMAPTDRD2DRD3HTR1A | |
| SCHEMBL19012760 | 0.81 | KDM4E (0.55) | KDM4EMAPTDRD2DRD3HTR1A | |
| SCHEMBL8145185 | 0.80 | KDM4E (0.60) | KDM4EMAPTDRD2DRD3HTR1A | |
| SCHEMBL6884485 | 0.78 | KDM4E (0.65) | KDM4EMAPTDRD2DRD3HTR1A | |
| Hydrochloric Acid SCHEMBL8401502 | 0.77 | KDM4E (0.68) | KDM4EMAPTDRD2DRD3HTR1A | |
| SCHEMBL24045832 | 0.77 | KDM4E (0.56) | KDM4EMAPTDRD2DRD3HTR1A | |
| SCHEMBL4558892 | 0.76 | KDM4E (0.71) | KDM4EMAPTDRD2DRD3HTR1A | |
| SCHEMBL20428029 | 0.75 | KDM4E (0.65) | KDM4EMAPTDRD2DRD3HTR1A | |
| SCHEMBL13591224 | 0.75 | KDM4E (0.65) | KDM4EMAPTDRD2DRD3HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9938292-B2 | Quinoline derivatives as SMO inhibitors | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2018-04-10 | — | — | US | disclosed |
| US-9938292-B2 | Quinoline derivatives as SMO inhibitors | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2018-04-10 | — | — | US | disclosed |
| US-20170174703-A1 | QUINOLINE DERIVATIVES AS SMO INHIBITORS | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2017-06-22 | — | — | US | disclosed |
| US-20170174703-A1 | QUINOLINE DERIVATIVES AS SMO INHIBITORS | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174703-A1 | QUINOLINE DERIVATIVES AS SMO INHIBITORS | SMO, GLI1, SHH | KDM4E 415/4885MAPT 4195/4885DRD2 3066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.